Dr. Gbola Amusa is Partner and Head of Healthcare Research at Chardan. Dr. Amusa joined Chardan at the end of 2014 to focus on identifying companies that will generate exceptionally high long-term investment returns from creating and sharing in real value for society. Dr. Amusa’s coverage of disruptive biotech, top picks, and counter-consensus calls have all since been associated with exceptional alpha generation over the years, with Dr. Amusa for example finishing ranked #2 out of over 6,000 Wall Street analysts in 2019 for his stock-picking performance in a study by TipRanks.
Dr. Amusa was previously Managing Director, Head of European Pharma Research, and Global Pharma & Biotech Coordinator at UBS, where he oversaw 25 analysts, and ultimately finished as the #1 ranked European pharma analyst in the Institutional Investor (II) Survey. Prior to UBS, Dr. Amusa was a Senior Research Analyst and Head of European Pharma research at Sanford Bernstein. He started his career in finance at Goldman Sachs as an Associate in the Healthcare Investment Banking Group, where he worked on large transactions including the Amgen/Immunex merger. Additionally, Dr. Amusa was previously a Healthcare Finance & Strategy Consultant working with governments, companies, leading foundations and think tanks. Dr. Amusa’s views on healthcare have been cited by socially responsible investing (SRI), ESG and sustainability organizations like FSG/Shared Value Initiative, GMI Ratings and the ATM Index.
Dr. Amusa earned his BSE with honors in biomedical engineering from Duke University, an MD from Washington University Medical School, and his MBA (GPA 4.0/4.0) from the University of Chicago, Booth School of Business.
We've received your information, and we're processing your request.